

Additional data from Affibody's HER2 radiopharmaceutical program presented at PepTalk

Affibody AB ("Affibody") announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented today at the annual PepTalk conference.

The data will be presented in the Targeted Radioligand Therapies session at the 24th annual PepTalk conference on January 15, 2025.

"The data at hand suggest that our drug candidate could reach meaningful levels of drug in tumors of patients with HER mediated disease" says Fredrik Frejd, CSO, Affibody AB. "We have recently filed a clinical trial application and anticipate early clinical data by mid year", he continues.

The presentation details are as follows:

Title: *Expanding Targeted Radioligand Therapy to HER2-Expressing Breast Cancer Using Affibody Molecules as Targeting Vectors.*

Presenter: Prof. Fredrik Frejd, CSO Affibody.

Session: Targeted Radioligand Therapies.

Time and date: January 15, 2025, 08:20 am PST.

Additional information is available at: <https://www.chi-peptalk.com/targeted-radioligand-therapies#2>

About ABY-271

ABY-271 is a radiotherapeutic candidate aimed at tumor cells that express HER2, regardless of their position in the body. The project builds on previous clinical research insights from the development of tezatabep (ABY-025), showing that the candidate substance can bind to HER2 independently of the tumor origin. ABY-271 emits therapeutic beta radiation, exerting irreversible damage to the cancer cells upon binding. The drug candidate is currently in late IND enabling development.

About Affibody® molecules

Affibody® molecules are a novel drug class of small therapeutic proteins with characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments. The Company has created a large library consisting of more than ten billion Affibody® molecules, all with unique binding sites, from which binders to given targets are selected. Affibody® molecules are only 6 kDa in size.

They have demonstrated clinical utilities both as tumor-targeting moieties through their small size and as efficacious disease blocking agents in autoimmune indications by utilizing the inherent properties that allow multi-specific formats.

About Affibody

Affibody is a clinical stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody® molecules.

Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Disclaimer

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Contacts

Affibody

David Bejker, CEO, +46 706 454 948

Peter Zerhouni, CFO and CBO, +46 706 420 044

Affibody Media Contact

Richard Hayhurst/Ola Björkman, RHA Communications, +44 7711 821 527, richard@rhacomms.eu

Attachments

[Additional data from Affibody's HER2 radiopharmaceutical program presented at PepTalk](#)